Synthetic Lung Surfactant for Respiratory Distress Syndrome

Back to all technologies
Download as PDF
Respiratory distress syndrome (RDS) causes nearly 40 percent of premature infant deaths worldwide. A lack of natural surfactant in their under-developed lungs is the initial cause of RDS. Treatment is not readily available for RDS in developing countries because conventional surfactant replacement therapy uses animal-derived surfactants that are costly to produce, must be carefully stored, and require highly trained practitioners to perform a sophisticated delivery procedure.

Researchers from Purdue University have developed a synthetic polymer-based surfactant to treat RDS by supplementing the premature infant's naturally produced surfactants. The synthetic lung surfactant, proven effective by in vitro measurements using a lung-mimetic device, will be less expensive to produce and store and will not require delivery by skilled physicians. This simple, cost effective surfactant is a promising treatment to decrease the mortality rate of premature infants worldwide.

-Less costly to produce and store
-Less variation in production versus current animal-derived surfactant
-Treatment option for developing countries

Potential Applications:
-Respiratory distress syndrome
Jan 26, 2018
United States

Aug 11, 2017

Aug 12, 2016
United States
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486